LifeMD, Inc.
No enriched coverage for $LFMD in the last 7 days.
No SEC Form 4 filings for $LFMD in the last 30 days.
See all $LFMD insider activity →LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.
LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.
LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21%
Recent LFMD coverage spans financial news, earnings and sector analysis.
Guidance reset plus profitability pressure from acquisition and pricing changes is likely to drive near-term valuation and positioning around 2H 2026 margin recovery.
Earnings and guidance cut drove a sharp after-hours selloff, with investors repricing 2026 growth and profitability trajectory.
Guidance revision and Q2 operating metrics (gross margin, subscriber growth, cash/liquidity) set a near-term valuation and risk framework for LFMD’s path to positive adjusted EBITDA in 2H26.
The article is a catalyst stack for LFMD, but it is primarily an analyst reiteration rather than a new company disclosure.
Preferred dividend authorization is a direct capital-return/cash-flow signal for LFMD’s preferred equity and can influence preferred pricing and equity sentiment at the margin.
alphai scores every news story that mentions LFMD with an AI model for sentiment and relevance, and aggregates insider trades from LifeMD, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.
6 min readLifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.
4 min readLifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21%
6 min readB. Riley Securities reiterated LifeMD Inc. as its top digital health pick after its 26th Annual Institutional Investor Conference. The firm rates LFMD Buy, with a $10 price target, citing a telehealth collaboration with Antares for XYOSTED, Medicare GLP-1 coverage via Humana, and potential FDA compounding changes. It also cites LifeMD Q1 2026 revenue of $50.2M and EPS of -$0.20.
4 min readLifeMD, Inc. (Nasdaq: LFMD) said its board authorized a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) of $0.5546875 per share. The dividend will be paid July 15, 2026, to holders of record as of July 3, 2026.
2 min readLifeMD (Nasdaq: LFMD) appointed Umesh Sripad as Chief Technology Officer effective immediately, according to the company. He will lead technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and scalability. LifeMD said it has grown to a 50-state virtual primary/specialty care and pharmacy platform serving nearly 350,000 patients. The company will grant 150,000 RSUs as an inducement.
3 min readLifeMD, Inc. (LFMD) has awarded its Chief Financial Officer, Atul Kavthekar, 337,500 restricted stock units (RSUs) as part of a compensation grant. These RSUs were granted at a price of $0.00 per share and will vest in three equal tranches on March 16, 2027, March 16, 2028, and March 16, 2029, aligning his compensation with multi-year service. Following this grant, Kavthekar directly holds 337,500 shares.
2 min readLifeMD Inc. (LFMD) reported a strong Q4 and full-year 2025, with a 25% annual revenue increase and strategic advancements in AI and healthcare services. Despite a GAAP net loss for the quarter and anticipated Q1 2026 EBITDA loss due to high marketing investments in its GLP-1 weight loss business, the company is optimistic about future growth driven by new patient acquisitions, expanding services like Oral Wegovy, and AI integration. LifeMD is entering 2026 with a strong balance sheet, nearly 323,000 active subscribers, and no debt.
5 min readJump Financial LLC increased its stake in LifeMD, Inc. (NASDAQ:LFMD) by 205.0% in the second quarter, acquiring an additional 346,171 shares, bringing its total holdings to 515,052 shares valued at $7,015,000. Other institutional investors like Connor Clark & Lunn, Geode Capital Management, and JPMorgan Chase also adjusted their positions in the telehealth company. Despite mixed analyst ratings, with six firms issuing a Buy and one a Hold, the stock has a consensus "Hold" rating and an average target price of $9.25.
3 min readTDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.
4 min read
